cbdMD Lifts Revenue 20% as Cost Cuts Chase Breakeven

cbdMD Inc (NYSE American: YCBD) told investors on its fiscal Q3 2026 earnings call that revenue grew 20%, driven by wholesale distribution and its Oasis brand, while the company pushes aggressive cost reductions to lower its breakeven point amid a shifting CBD regulatory landscape; the shares closed at $0.56, down 5.52%.

cbdMD Inc (NYSE American: YCBD) used its fiscal third-quarter 2026 earnings call to make a straightforward case: the top line is growing again, and the cost base is being cut hard enough to bring the company closer to breakeven. Management pointed to 20% revenue growth, credited wholesale distribution and the Oasis brand for that momentum, and described a program of aggressive cost reductions designed to lower the sales level at which the business stops burning money.

The market was not impressed on the day. cbdMD shares closed at $0.56 on Thursday, down 5.52% from the prior close of $0.60, with a session range of $0.56 to $0.61 — a close at the bottom of the day's band. That came against a broadly positive tape: the S&P 500 ETF (SPY) finished at $777.88, up 0.70%, and the Nasdaq 100 ETF (QQQ) at $732.07, up 1.16%, as of the 20:00 GMT close on 13 August 2026.

Growth is real, but the shape of it matters

A 20% revenue increase is a genuine inflection for a company in the consumer CBD space, a category that has spent years contending with distribution limits, payment-processing friction and heavy discounting. What matters more than the headline percentage is where the volume came from.

Management attributed the gain to two drivers. The first is wholesale — selling through retailers and distributors rather than direct to the consumer online. Wholesale typically carries lower gross margin than direct-to-consumer, but it also comes with far lower customer-acquisition cost, because the retailer's shelf does the marketing. For a company trying to cut its way to breakeven, trading gross margin points for a big reduction in paid-media spend can be the right swap.

The second driver is the Oasis brand. Brand-level momentum is what investors in small consumer companies watch most closely, because it distinguishes growth that comes from a product people ask for by name from growth that comes from promotional pricing. cbdMD's framing on the call, as summarized by GuruFocus, was that of a strategic pivot rather than a cyclical bounce.

Why "lowering breakeven" is the operative phrase

Companies at this end of the market capitalization scale rarely get to grow into profitability. The arithmetic runs the other way: fixed costs have to come down until the existing revenue base can cover them. That is precisely what management described — cost reductions aimed at lowering the breakeven point, not a promise that sales will eventually be large enough to absorb today's overhead.

The distinction is important for anyone assessing the risk here. If breakeven is being pulled down toward current revenue, then a 20% growth rate compounds directly into operating leverage. If the cuts hit marketing, product development or sales headcount hard enough to stall the top line, the company can end up chasing a moving target — cutting to a breakeven level it no longer reaches. That tension between cost discipline and growth investment is the single most useful thing to track over the next two quarters.

The company did not, in the material available, put a public number on the cash position, the quarterly loss or the revised breakeven revenue level. Those figures — cash on hand, operating cash burn per quarter, and the gross margin achieved on the newer wholesale mix — are what will determine whether the pivot has time to work. Until they are in front of investors, the 20% growth figure is a signal of direction rather than proof of survival.

Regulation remains the variable nobody at the company controls

The call also flagged a shifting regulatory landscape. For hemp-derived CBD, that phrase covers a lot of ground: federal rules on ingestible products, state-by-state restrictions on hemp-derived cannabinoids, labeling and potency requirements, and the perennial question of how national retailers interpret their own compliance risk.

Regulatory movement cuts both ways for a company like cbdMD. Clearer federal rules would legitimize shelf space at large chains and could be a meaningful tailwind for exactly the wholesale channel now driving growth. Restrictive state action, by contrast, can remove entire markets with little notice and strand inventory built for them. A company leaning into wholesale is more exposed to the second scenario than a direct-to-consumer seller, because retail partners tend to de-list quickly when compliance questions surface.

That asymmetry helps explain why a 20% growth print did not lift the stock. At $0.56 a share, the market is pricing a business whose operating improvement is credible but whose regulatory and financing risks are unresolved.

What to watch in the next two reports

Several concrete markers will tell investors whether the pivot is working:

• Gross margin trend. If the wholesale shift is margin-dilutive, the percentage should compress even as revenue grows. Watch whether the dollar gross profit still rises.
• Operating expense run rate. The cost program should show up as a step down in absolute selling, general and administrative spend, not just a lower ratio to sales.
• Oasis contribution. Any disclosure that separates Oasis revenue from the legacy cbdMD line will show whether the brand is additive or cannibalizing.
• Cash and financing. Sub-dollar share prices constrain capital raising. Any equity issuance would be dilutive at these levels; any debt would add fixed cost to a business trying to remove it.
• Listing standards. A share price under $1 is a live consideration for any NYSE American-listed company, and investors should follow company disclosures on that front rather than assume anything.

How the stock sits against the broader market

The wider tape on 13 August 2026 was constructive. All three major benchmark ETFs closed higher: SPY at $777.88 (+0.70%), QQQ at $732.07 (+1.16%) and the Dow 30 ETF (DIA) at $537.91 (+0.14%). cbdMD's 5.52% decline against that backdrop is the clearest evidence that the earnings call did not resolve the questions investors care about most.

That is a familiar pattern in micro-cap turnarounds. Revenue growth and cost cuts are necessary conditions for a re-rating, but they are not sufficient. What converts an operating story into a share price is evidence that the company can fund itself to the point where the two lines cross. cbdMD has now told the market it is heading there. The next set of numbers will show how far away it still is.

Frequently asked questions

How much did cbdMD's revenue grow in fiscal Q3 2026?

cbdMD reported 20% revenue growth for its fiscal third quarter of 2026. On the earnings call, management attributed the increase to two sources: expansion of its wholesale distribution channel, meaning sales through retailers and distributors, and momentum behind its Oasis brand. The company did not publicly detail a dollar revenue figure in the available material.

Where did cbdMD stock close?

cbdMD Inc trades on NYSE American under the symbol YCBD. It last traded at $0.56, a decline of 5.52% from the previous close of $0.60, with a session range of $0.56 to $0.61. That price is as of the 20:00 GMT close on 13 August 2026. The market was closed at the time of writing.

What does 'lowering the breakeven point' mean here?

It means cutting fixed and operating costs so that a smaller amount of revenue is enough to cover them. Rather than waiting for sales to grow large enough to absorb existing overhead, cbdMD is reducing overhead toward its current sales base. If revenue keeps rising while costs fall, the two lines cross sooner.

Why did the stock fall despite the revenue growth?

cbdMD fell 5.52% on a day when the S&P 500 ETF rose 0.70% and the Nasdaq 100 ETF gained 1.16%. The likely explanation is that growth and cost cuts alone do not resolve the questions investors weigh most for a sub-dollar stock: cash runway, gross margin under a wholesale mix, and unresolved regulatory exposure.

What regulatory risk does cbdMD face?

Management described a shifting regulatory landscape. For hemp-derived CBD companies, that spans federal treatment of ingestible products, varying state restrictions on hemp-derived cannabinoids, and labeling or potency requirements. A wholesale-weighted business is particularly exposed, because national retail partners tend to de-list products quickly when compliance questions arise.

What should investors watch in cbdMD's next results?

Four things: whether dollar gross profit rises even if margin percentage compresses under the wholesale mix; whether absolute operating expenses step down as the cost program lands; any separate disclosure of Oasis brand revenue; and the cash position alongside any financing, since raising equity below $1 a share is heavily dilutive.

Sources

• cbdMD Inc (YCBD) (Q3 2026) Earnings Call Highlights: Strategic Pivot and Cost Cuts Aim to ... — GuruFocus

Photo: cottonbro studio · Pexels Licence — source